Literature DB >> 31285395

Neuropsychiatric Sequelae in Adolescents With Acute Synthetic Cannabinoid Toxicity.

Sarah Ann R Anderson1, Anna M Oprescu2, Diane Calello3, Andrew Monte4, Peter S Dayan5,6, Yasmin L Hurd2, Alex F Manini7.   

Abstract

BACKGROUND AND OBJECTIVES: Adolescents represent the largest age group that presents to emergency departments (ED) for synthetic cannabinoid (SC) toxicity; however, the neurotoxic effects of acute SC exposures in this group are understudied. Our aim was to characterize the neuropsychiatric presentation of adolescents with SC-related exposure in the ED compared with those with traditional cannabis exposure.
METHODS: A multicenter registry of clinical information prospectively collected by medical toxicologists (Toxicology Investigators Consortium Case Registry) was reviewed for adolescents presenting to the ED after SC or cannabis exposure from 2010 through 2018. Associations were measured between drug exposures and neuropsychiatric symptoms and/or signs. Exposures were classified into 4 groups: SC-only exposure, SC-polydrug exposures, cannabis-only exposure, and cannabis-polydrug exposures.
RESULTS: Adolescents presenting to the ED with SC-only exposure (n = 107) had higher odds of coma and/or central nervous system depression (odds ratio [OR] 3.42; 95% confidence interval [CI] 1.51-7.75) and seizures (OR 3.89; 95% CI 1.39-10.94) than those with cannabis-only exposure (n = 86). SC-only drug exposure was associated with lower odds of agitation than cannabis-only exposure (OR 0.18; 95% CI 0.10-0.34). In contrast, the group with SC-polydrug exposures (n = 38) had higher odds of agitation (OR 3.11; 95% CI 1.56-7.44) and seizures (OR 4.8; 95% CI 1.80-12.74) than the cannabis-polydrug exposures group (n = 117).
CONCLUSIONS: In this multisite cohort of US adolescents assessed in the ED, SC exposure was associated with higher odds of neuropsychiatric morbidity than cannabis exposure providing a distinct neurospychiatric profile of acute SC toxicity in adolescents.
Copyright © 2019 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31285395      PMCID: PMC6697124          DOI: 10.1542/peds.2018-2690

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  30 in total

1.  The Toxicology Investigators Consortium Case Registry--the 2014 Experience.

Authors:  Sean H Rhyee; Lynn Farrugia; Sharan L Campleman; Paul M Wax; Jeffrey Brent
Journal:  J Med Toxicol       Date:  2015-12

2.  The Toxicology Investigators Consortium Case Registry-the 2010 experience.

Authors:  Jeffrey Brent; Paul M Wax; Tayler Schwartz; Kurt C Kleinschmidt; Kristin Engebretsen; Michael Beuhler
Journal:  J Med Toxicol       Date:  2011-12

3.  The Toxicology Investigators Consortium Case Registry--the 2012 experience.

Authors:  Timothy Wiegand; Paul Wax; Eric Smith; Katherine Hart; Jeffrey Brent
Journal:  J Med Toxicol       Date:  2013-12

4.  The Toxicology Investigators Consortium Case Registry-the 2017 Annual Report.

Authors:  Lynn A Farrugia; Sean H Rhyee; Sharan L Campleman; Bryan Judge; Louise Kao; Anthony Pizon; Lauren Porter; Anne M Riederer; Timothy Wiegand; Diane Calello; Paul M Wax; Jeffrey Brent
Journal:  J Med Toxicol       Date:  2018-08-09

5.  The toxicology investigators consortium case registry-the 2013 experience.

Authors:  Sean H Rhyee; Lynn Farrugia; Timothy Wiegand; Eric A Smith; Paul M Wax; Jeffrey Brent
Journal:  J Med Toxicol       Date:  2014-12

6.  A survey of synthetic cannabinoid consumption by current cannabis users.

Authors:  Erik W Gunderson; Heather M Haughey; Nassima Ait-Daoud; Amruta S Joshi; Carl L Hart
Journal:  Subst Abus       Date:  2014       Impact factor: 3.716

7.  Cannabinoids negatively modulate striatal glutamate and dopamine release and behavioural output of acute D-amphetamine.

Authors:  A Polissidis; O Chouliara; A Galanopoulos; G Naxakis; D Papahatjis; Z Papadopoulou-Daifoti; K Antoniou
Journal:  Behav Brain Res       Date:  2014-05-24       Impact factor: 3.332

8.  Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA.

Authors:  Maren Hermanns-Clausen; Dieter Müller; Josephine Kithinji; Verena Angerer; Florian Franz; Florian Eyer; Hartmud Neurath; Gesine Liebetrau; Volker Auwärter
Journal:  Clin Toxicol (Phila)       Date:  2017-10-26       Impact factor: 4.467

9.  Synthetic cannabinoid intoxication: a case series and review.

Authors:  Carson R Harris; Ashley Brown
Journal:  J Emerg Med       Date:  2012-09-16       Impact factor: 1.484

10.  Synthetic Cannabinoid Use Among High School Seniors.

Authors:  Joseph J Palamar; Monica J Barratt; Leigh Coney; Silvia S Martins
Journal:  Pediatrics       Date:  2017-09-11       Impact factor: 7.124

View more
  2 in total

1.  Behavioral and Molecular Responses to Exogenous Cannabinoids During Pentylenetetrazol-Induced Convulsions in Male and Female Rats.

Authors:  Antonella Zirotti Rosenberg; Maxs Méndez-Ruette; Mario Gorziglia; Benjamín Alzerreca; Javiera Cabello; Sofía Kaufmann; Lukas Rambousek; Andrés Iturriaga Jofré; Ursula Wyneken; Carlos A Lafourcade
Journal:  Front Mol Neurosci       Date:  2022-08-09       Impact factor: 6.261

2.  Chronic cannabinoid exposure produces tolerance to the dopamine releasing effects of WIN 55,212-2 and heroin in adult male rats.

Authors:  Devan M Gomez; Thomas J Everett; Lindsey R Hamilton; Ajit Ranganath; Joseph F Cheer; Erik B Oleson
Journal:  Neuropharmacology       Date:  2020-10-25       Impact factor: 5.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.